FindTrial
Sign In

Late Phase II study of Paricalcitol injection

Late Phase II study of Paricalcitol injection

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220559
Enrollment
Unknown
Registered
2008-05-19
Start date
2008-05-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary Hyperparathyroidism

Interventions

investigational material(s) Generic name etc : ABT-358 INN of investigational material : Paricalcitol Therapeutic category code : 311 Vitamin A, D and preparations Dosage and Administration for Invest

Sponsors

Abbott Japan Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Aged 20 or over Chronic kidney disease subjects receiving hemodialysis with secondary hyperparathyroidism

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The proportion of subjects with >=50% decrease from baseline in iPTH at the final visit—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026